Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | Neoadjuvant nivolumab (N) + chemotherapy - (CheckMate-816) | Non-small cell lung cancer (NSCLC) | Phase 3 | Data Released | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Opdivo (nivolumab) plus Yervoy (ipilimumab) - (CheckMate -9LA) | Metastatic non-small cell lung cancer (NSCLC) | Phase 3 | Data Released | Intravenous | Oncology |
| Bristol-Myers Squibb Company | BMS-986278 | Progressive pulmonary fibrosis (PPF) | Phase 2 | Data Released | Oral | Respiratory |
| Bristol-Myers Squibb Company | Opdivo (anti-PD1) - (CheckMate-1533) | 1L Non-small Cell Lung Cancer (NSCLC) SC + IV | Phase 2 | Trial Planned | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Abecma (idecabtagene vicleucel) - (KarMMa-2) | Newly diagnosed multiple myeloma | Phase 2 | Ongoing | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Milvexian - (AXIOMATIC-TKR) | Venous thromboembolism (VTE) prevention post total knee replacement (TKR) surgery | Phase 2 | Data Released | Oral | Anticoagulant |
| Bristol-Myers Squibb Company | Sitravatinib and tislelizumab | Hepatocellular Carcinoma (HCC) / Gastric / Gastroesophageal Junction Cancer | Phase 2 | Data Released | Intravenous | Oncology |
| Bristol-Myers Squibb Company | BMS-986504 (PRMT5 inhibitor) - (MountainTAP-30) | 1L Metastatic PDAC (with Homozygous MTAP deletion) | Phase 2/3 | Ongoing | oral | Oncology |
